InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,556.39
(
0.86%
)
US TECH 100
19,826.40
(
0.94%
)
Dow Jones
39,298.23
(
-0.02%
)
Brent Oil
87.27
(
-0.07%
)
Bitcoin
56,508.41
(
-0.83%
)
Post# of 252490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 62254

Saturday, 05/03/2008 6:50:06 PM

Saturday, May 03, 2008 6:50:06 PM

Post# of 252490
Musings on MNTA’s Valuation

Several posters have assigned probabilities to the four
mutually-exclusive cases described below to arrive at
the fair value figures shown in the following table. The
market caps and share prices corresponding to each
case pertain to the time interval approximately 9-12
months from today (Feb-Apr 2009), by which time
MNTA/Sandoz expects the FDA to have formally
responded to the companies’ ANDA resubmission.
Thus, the four cases below are defined in terms of
the FDA action on the next review cycle.

All posters are welcome to submit their own
probabilities or alternative analyses.
 
           ($57)  ($24)  ($11) ($5.5)  Fair  
          Case-1 Case-2 Case-3 Case-4  Value 
 ThomasS    70%    10%    20%     0%  $44.50 
 zipjet     50%    40%     0%    10%  $38.65 
 Dew        54%    28%    12%     6%  $39.15 
 JR*        20%    40%    25%    15%  $18.10 
 stockdak   20%    70%    10%     0%  $29.30 
 rkrw**     30%    15%    55%     0%  $21.75

*JR assigns prices of $35, $20, $10, $4 to the
four cases in lieu of the prices specified below.

**rkrw assigns prices of $40, $10, $15, $8 to the
four cases in lieu of the prices specified below


Description of the four cases:

The following background assumptions apply: MNTA continues to make steady, but not spectacular, progress on M118 and other non-Lovenox programs; the US passes legislation enabling follow-on biologics during 2008 or 2009; MNTA does not sell shares before the status of the Lovenox ANDA is cemented; Sanofi fails to reinstate its US Lovenox patent; MNTA does not receive a buyout offer.

Case 1: MNTA/Sandoz obtains approval for generic Lovenox and neither Teva nor Amphastar obtain approval, (Sanofi may launch an authorized generic, but it would be the only generic in the market other than the one from MNTA/Sandoz.) Market cap: $2.1B; share price: $57.

Case 2: MNTA/Sandoz obtains approval for generic Lovenox; Teva, Amphastar, or both obtain approval too. Market cap: $900M; share price: $24.

Case 3: The FDA formally responds to the MNTA/Sandoz ANDA resubmission with new questions or requests. Market cap: $400M; share price: $11.

Case 4: FDA rejects MNTA/Sandoz’s Lovenox ANDA with no possibility of a resubmission. Market cap: $200M; share price: $5.50.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up